Comments
Zydus Cadila on Friday announced that the company has received approval from the US drug regulator, US Food and Drug Administration to market Doxycycline Capsules USP.
In a statement here, the company stated that it has received approval from the USFDA to market 50 mg, 75 mg, and 100 mg Capsules of the the anti-bacterials segment drug.
"With this first approval, the group will now commence supplies to the US market from its formulation manufacturing facility located at the SEZ in Ahmedabad," the statement said.
The group now has 102 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.